For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Constellation Pharmaceuticals, Inc.

USPTO Granted Patents = 56

% Expired Patents = 1.8

EPO Patents = 43

Forward Citations = 215

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

Brian K Albrecht (35 out of 52 patents)

Victor S Gehling (32 out of 32 patents)

Christopher G Nasveschuk (25 out of 65 patents)

4. Jean-Christophe P Harmange (22 out of 57 patents)

5. Alexander M Taylor (18 out of 28 patents)

6. Rishi G Vaswani (17 out of 27 patents)

7. James E Audia (16 out of 99 patents)

8. Steven R Magnuson (15 out of 44 patents)

9. Vickie Hsiao-Wei Tsui (12 out of 26 patents)

10. F Anthony Romero (12 out of 42 patents)

11. Martin Duplessis (12 out of 29 patents)

12. Alexandre Cote (12 out of 12 patents)

13. Alexandre Côté (11 out of 11 patents)

14. Michael Charles Hewitt (11 out of 33 patents)

15. Les A Dakin (11 out of 11 patents)

Core Competencies:

TREX1 Modulators

Myeloproliferative Disorders

Methyl Modifying Enzymes

LSD1 Inhibitors

P300/CBP HAT Inhibitors

EZH2 Inhibitors

Histone Demethylase Inhibitors

Bromodomain Inhibitors

Therapeutic Compounds

Pyrazolo Compounds

Indole Derivatives

Crystalline Forms

56 patents: Sort by Forward Citations

1. 12612390 - Modulators of methyl modifying enzymes, compositions and uses thereof (2026-04-28),

2. 12516040 - Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (2026-01-06),

3. 12172990 - Modulators of TREX1 (2024-12-24),

4. 12070464 - Methods of treating myeloproliferative disorders (2024-08-27),

5. 11919912 - Modulators of methyl modifying enzymes, compositions and uses thereof (2024-03-05),

6. 11547695 - LSD1 inhibitors and medical uses thereof (2023-01-10),

7. 11459315 - Modulators of methyl modifying enzymes, compositions and uses thereof (2022-10-04),

8. 11414384 - P300/CBP hat inhibitors (2022-08-16),

9. 11274095 - Modulators of methyl modifying enzymes, compositions and uses thereof (2022-03-15),

10. 11274090 - P300/CBP HAT inhibitors (2022-03-15),

11. 11247989 - Therapeutic compounds and uses thereof (2022-02-15),

12. 11168070 - Therapeutic compounds and uses thereof (2021-11-09),

13. 11013718 - LSD1 inhibitors and medical uses thereof (2021-05-25),

14. 10918646 - Methods of treating myeloproliferative disorders (2021-02-16),

15. 10696655 - Therapeutic compounds and uses thereof (2020-06-30),

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapeutics targeting gene expression in cancer and other diseases. With a focus on utilizing insights from epigenetics, Constellation is advancing a robust pipeline of potential medicines to address the serious unmet needs of patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Constellation Pharmaceuticals, Inc.

56 Patents

#46 in Cambridge, MA

#359 in Massachusetts

#6,334 in US

#12,708 in the World

Cambridge, MA, United States of America

Constellation Pharmaceuticals, Inc.

Forward Citations = 215

65 inventors:

Brian K Albrecht (35 out of 52 patents)

Victor S Gehling (32 out of 32 patents)

Christopher G Nasveschuk (25 out of 65 patents)

4. Jean-Christophe P Harmange (22 out of 57 patents)

5. Alexander M Taylor (18 out of 28 patents)

Please report any incorrect information to [email protected]

Loading…